Clinical trials: Coagulation, Blood
Haemophilia
Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B
Severe haemophilia A and B (SHA, SHB) are X - linked inherited bleeding disorders, characterised by factor VIII and IX levels of <1 IU/dL respectively.
- Trial name
- InPath (NCT03287999)
- Testing
- Thrombophilia screen, Initiation pathway analysis
- Where
- United Kingdom
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Systemic Lupus Erythematosus, Immune Thrombocytopenia
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
The goal of this clinical trial is to learn if sirolimus, added to standard background therapy (corticosteroids and hydroxychloroquine), works to treat systemic lupus erythematosus-associated immune thrombocytopenia (SLE-ITP) in…
- Trial name
- NCT07657793
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Chinese SLE Treatment And Research Group
Chronic Pain, Depression Disorders
Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study
What is the purpose of this study? The use of medicinal cannabis has grown significantly in Brazil. However, because many patients use these products through "compassionate use" (when traditional treatments haven't worked), there…
- Conditions
- Chronic Pain, Depression Disorders, Anxiety Disorders, Quality of Life
- Trial name
- CANAREAL (NCT07362407)
- Testing
- Participants are followed while using cannabis-based products (such as CBD or THC oils, extracts, or isolates) as prescribed by their own physicians for therapeutic purposes.
- Where
- Brazil
- Volunteers
- 384 people
- Sponsor
- Santa Catarina Federal University
Anemia, Chronic Myeloproliferative Disorders
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy, such as busulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00301912
- Testing
- filgrastim, busulfan, fludarabine phosphate
- Where
- United States
- Sponsor
- University of California, San Francisco
Essential Thrombocythemia
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
- Trial name
- EXCALIBUR-ET2 (NCT07623200)
- Testing
- INCA033989, Best Available Treatment
- Where
- 178 sites in United States, Australia and 17 more
- Volunteers
- 426 people
- Sponsor
- Incyte Corporation
Immune Thrombocytopenia
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment.
- Trial name
- LUNA 4 (NCT07007962)
- Testing
- rilzabrutinib
- Where
- 36 sites in United States, Austria and 7 more
- Volunteers
- 60 people
- Sponsor
- Sanofi
Hemophilia A, Hemophilia B
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior…
- Trial name
- NCT05568719
- Testing
- Testing of hepatic AAV Vector integration
- Where
- 39 sites in United States, Australia and 11 more
- Volunteers
- 173 people
- Sponsor
- Pfizer
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 1
The investigators study aims to test the correlation between the CoaguChek point-of-care testing (POCT) device (Roche, Switzerland) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC…
- Trial name
- POCT-DOAC 1 (NCT02371044)
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Immune Thrombocytopenia, Treatment
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This single-arm, open-label phase II study aim to evaluate the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) combined with Rituximab in ITP patients.This study will be conducted in ITP patients who had not…
- Trial name
- NCT07362199
- Testing
- Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Anticoagulants; Increased, Anticoagulant Overdosage
Noninvasive Measurement of Blood Coagulation
The investigators have developed an optical system that measures the coagulation status of patients in vivo in a non-invasive manner.
- Conditions
- Anticoagulants; Increased, Anticoagulant Overdosage, Coagulation Disorder, Blood Clot
- Trial name
- NCT03217799
- Testing
- Measurement of coagulability of blood
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.
Aim of this trial is to assess the pharmacokinetics and pharmacodynamics (PK/PD) of recombinant human coagulation factor VIIa for injection (FⅦa) in patients with hemophilia.
- Trial name
- NCT04768699
- Testing
- TQG203, TQG203/NovoSeven®
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Acute Myeloid Leukemia, Myeloproliferative Neoplasms
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
The objective of this study is to describe the prevalence and prognostic impact of the most common genetic abnormalities in patients with Myeloid Neoplasms, including Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms…
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Myelodysplastic Syndromes, Myeloproliferative/Myelodysplastic Neoplasm
- Trial name
- NCT02084563
- Testing
- Induction Chemotherapy, Consolidation Chemotherapy, Autologous Stem Cell Transplantation
- Where
- Brazil
- Volunteers
- 455 people
- Sponsor
- Hospital Israelita Albert Einstein
Hemophilia
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
The purpose of this study is to examine the safety, tolerability and the way the body handles various single and multiple doses of ARC19499 in patients with hemophilia.
- Trial name
- NCT01191372
- Testing
- ARC19499
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Baxalta now part of Shire
Acquired Bleeding Disorder, Trauma
Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy of activated recombinant human factor VIIgiven in conjunction with standard therapy in patients undergoing major orthopaedic surgery following…
- Trial name
- NCT01601457
- Testing
- activated recombinant human factor VII
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Kidney Replacement Disorder
Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy
Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy.
- Trial name
- NCT01276392
- Where
- Germany
- Sponsor
- Klinik für Anästhesiologie
Immune Thrombocytopenia
Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)
This is a single center, open-label, 3+3 dose escalation, early phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of PRG-1801 for patients with relapsed/refractory immune thrombocytopenia (ITP).
- Trial name
- NCT06519565
- Testing
- PRG-1801
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hemophilia A With Inhibitor
The Hemophilia Inhibitor Eradication Trial
This is a multi-center randomized phase III clinical trial, the Inhibitor Eradication Trial, in which Eloctate ITI plus Emicizumab will be compared with Eloctate ITI alone to eradicate inhibitors in severe hemophilia A.
- Trial name
- NCT04303572
- Testing
- Eloctate ITI, Emicizumab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Margaret Ragni
Wiskott-Aldrich Syndrome
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
This is a prospective, open-label, randomized, two-arm clinical trial conducted to evaluate the safety and efficacy of romiplostim in comparison with eltrombopag in the treatment of thrombocytopenia in patients with…
- Trial name
- NCT04371939
- Testing
- Romiplostim, Eltrombopag
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hemophilia
Conditioned Pain Modulation in Patients With Hemophilia
Introduction: Hemophilic arthropathy is characterized by functional alterations, disabling physical sequelae, and chronic pain. Conditioned pain modulation describes the net effect of endogenous pathways that enhance or diminish…
- Trial name
- NCT06267209
- Testing
- Observational group
- Where
- Spain
- Volunteers
- 51 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Blood Coagulation Disorder, Postoperative Blood Loss
Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery
Tranexamic axid is routinely used as an antifibrinolytic agent in cardiac surgery to reduce the risk of blood loss and transfusion.
- Conditions
- Blood Coagulation Disorder, Postoperative Blood Loss, Adverse Drug Event, Fibrinolysis; Hemorrhage
- Trial name
- NCT07164300
- Testing
- Tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h, Tranexamic acid at a dose of 20 mg/kg, Tranexamic acid at a dose of 30 mg/kg
- Where
- Greece
- Volunteers
- 150 people
- Sponsor
- University of Ioannina